The content on this site is intended for healthcare professionals only
Dr Evans presents results from a study on the use of a novel, noninvasive imaging tool that allows researchers to measure free prostate-specific antigen in prostate cancer models and to visualise bone metastasis in a tumour-specific manner.
The results were presented at the AACR 2012 Annual meeting in Chicago.
ecancerNews Coverage: Novel technology allows for noninvasive imaging of prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
Looking at real world evidence on PSA testing in prostate cancer
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems
Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP
AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer
